US 11,730,705 B2
Small molecule CMKLR1 antagonists in inflammatory disease
Sanjay Malhotra, Palo Alto, CA (US); Vineet Kumar, Palo Alto, CA (US); Melissa LaJevic, Mountain View, CA (US); Mallesh Pandrala, Palo Alto, CA (US); and Brian A. Zabel, Redwood City, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US); and The United States Government As Represented By The Department of Veterans Affairs, Washington, DC (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US); and The United States Government As Represented By The Department of Veterans Affairs, Washington, DC (US)
Filed on Apr. 13, 2020, as Appl. No. 16/847,186.
Claims priority of provisional application 62/841,990, filed on May 2, 2019.
Prior Publication US 2020/0345661 A1, Nov. 5, 2020
Int. Cl. A61K 31/135 (2006.01); A61P 17/06 (2006.01); A61K 31/14 (2006.01); A61K 31/133 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/135 (2013.01) [A61K 31/133 (2013.01); A61K 31/14 (2013.01); A61P 17/06 (2018.01); A61P 25/28 (2018.01)] 8 Claims
 
1. A method of decreasing psoriasis in a subject, the method comprising:
administering to said subject an effective amount of a compound selected from

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry